Priority Date: 20.12.10 (US 201061424961P)

Combination therapy comprising Gemcitabine for the treatment of pancreatic cancer

  • Application ID: EP11851046
  • Status: PATENT GRANTED

Applicant

Technology company logo small
Technology Company

Attorneys

no operation time available
3 offices
Technology Company
no operation time available
1 office
Technology Company

Specialization

This EP application has the IPC class A61 (MEDICAL OR VETERINARY SCIENCE; HYGIENE). GlaxoSmithKline and Novartis Pharma AG are specialized in A61. GlaxoSmithKline, Novartis Pharma AG is specialised in A61 (MEDICAL OR VETERINARY SCIENCE; HYGIENE). Here you find a list of all patent agent firms which are specialized in this IPC class. For a similar patent, they might be a good choice.

Timeline

  • 20.12.2010 - Priority Date (US 201061424961P)
  • 28.06.2012 - Publication A1 (WO2012088030)
  • 30.10.2013 - Publication A1 (EP2654755)
  • 17.08.2016 - Publication B1 (EP2654755)